Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.58 |
| ▸ | DRD3 | P35462 | 13/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469487 | 0.94 | SLC6A2 (0.52) | DRD2DRD3SLC6A2SLC6A3LMNA | |
| SCHEMBL12469226 | 0.85 | ALDH1A1 (0.48) | DRD2DRD3LMNAHTR2AALDH1A1 | |
| SCHEMBL12469002 | 0.84 | ALDH1A1 (0.58) | SLC6A2SLC6A3LMNATP53SLC6A4 | |
| SCHEMBL12469349 | 0.83 | SLC6A2 (0.56) | SLC6A2SLC6A3LMNATP53ALDH1A1 | |
| SCHEMBL12469049 | 0.78 | ALDH1A1 (0.48) | LMNAALDH1A1POLBHPGDTSHR | |
| SCHEMBL12469317 | 0.77 | NPSR1 (0.61) | DRD2DRD3SLC6A2SLC6A3HTR2A | |
| SCHEMBL12469234 | 0.77 | ALDH1A1 (0.61) | SLC6A2SLC6A3LMNATP53ALDH1A1 | |
| SCHEMBL12469411 | 0.76 | SLC6A2 (0.52) | DRD2SLC6A2SLC6A3LMNATP53 | |
| SCHEMBL12468808 | 0.75 | DRD2 (0.58) | DRD2DRD3HTR2ADRD4ADRA1A | |
| SCHEMBL10973042 | 0.73 | ALDH1A1 (0.71) | LMNATP53ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | DRD2 2163/4885DRD3 2127/4885SLC6A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.